Approximately 70% of bladder transitional epithelium cell carcinomas are non-invasive muscular bladder cancers, and for the treatment and prevention of recurrence of this type of cancer, Bacillus Calmette-Guerin (BCG) is applied prophylactically. This practice is generally considered reliable and rarely causes systemic complications. We present here a case in which the patient underwent transur...

Henoch Schönlein purpura (HSP), also known as IgA vasculitis (IgAV), is a systemic small-vessel vasculitis that predominantly affects adolescents and is rare in adults. In many cases, the onset of HSP has been causally linked to an infectious disease. We encountered a case of HSP with severe renal involvement diagnosed by renal biopsy following bacillus Calmette-Guerin (BCG) therapy for bladder...

As a treatment for superficial transitional cell carcinoma, Bacillus Calmette-Guerin (BCG) intravesical instillation can rarely cause unpredictable systemic side effects. We describe a patient admitted due to continuous pyrexia and general fatigue. He was previously treated with intravesical BCG. Laboratory data indicated a hepatic disorder, and chest computed tomography revealed extensive bila...

For more than 70 years, Bacillus Calmette-Guerin (BCG) vaccines have been administered safely to billions of individuals throughout the world. Local adverse reactions following BCG vaccination usually occur at a rate of 0.1 to 0.5 per 1000 vaccinations, and serious, disseminated complications occur at a rate of less than 1 in a million vaccinations [1]. Physicians should be aware of the various...

GROVE, D. I., AND CIVIL, IL H. 1978. Trichinella spiralis: Effects on the host-parasite relationship in mice of BCG (attenuated Mycobacterium bovis). Experimental Parasitology 44, 181-189. The effects of BCG (Bacillus Calmette-Guerin, i.e., attenuated Mycobacterium bovis) on the host-parasite relationship in murine trichinosis were examined. A total of 2 X 10’ colony forming units of BCG given ...

Treatment options for patients with non-muscle invasive bladder cancer (NMIBC) refractory to intravesical bacillus Calmette-Guerin (BCG) therapy is reviewed in this article based on the recent published literature. Although intravesical BCG is the best bladder sparing treatment option for NMIBC to prevent recurrence and progression, about 1/3 of cases are refractory to this treatment. At this p...

Bacillus Calmette-Guerin (BCG) therapy has been proven to be effective treatment for superficial bladder carcinoma with complications that are usually minor and self limited. Although rare, granulomatous hepatitis can develop, and it is important to recognize it and treat it promptly. The hepatitis which occurs appears to be the result of a hypersensitivity reaction to antigens present in the B...

Epidemiological studies have suggested that the recent increase in the incidence and severity of immunoglobulin (Ig)E-mediated allergic disorders is inversely correlated with Mycobacterium bovis bacillus Calmette Guerin (BCG) vaccination; however, the underlying mechanisms remain uncertain. Here, we demonstrate that natural killer T (NKT) cells in mice and humans play a crucial role in the BCG-...

Results of a randomized prospective study are reported in which mitomycin C, Tice bacillus Calmette-Guerin (BCG) and RIVM-BCG were compared in 437 patients with primary or recurrent pTa and pT1 bladder tumors, including carcinoma in situ. The followup (or time in study) varied from 2 to 81 months (mean 36 months). After complete transurethral resection of all visible tumors the patients were tr...